ATS 2026

ATS 2026 Exhibitor: AI Lung Analysis, CAD & BLVR by Coreline

Coreline Soft will participate in ATS 2026 (American Thoracic Society International Conference) as an exhibitor, presenting AI-powered lung analysis solutions for pulmonary disease assessment and treatment planning.

ATS 2026, held from May 15–20 in Orlando, brings together global experts across pulmonary, critical care, and sleep medicine, along with companies spanning pharmaceuticals, medical devices, and digital health.

Within this ecosystem, AI-powered imaging companies are an emerging segment, particularly in lung CT analysis, disease monitoring, and clinical decision support.

 

AI for Lung Analysis and Treatment Planning

Coreline focuses on advancing AI from image interpretation to clinical decision support, especially in respiratory diseases such as:

• Chronic obstructive pulmonary disease (COPD)
• Interstitial lung disease (ILD)
• Lung cancer

AI-based quantitative analysis (CAD) enables:

• Objective assessment of lung structure and disease patterns
• Reproducible measurement across time and institutions
• Support for clinical decision-making

 

Supporting BLVR with Quantitative Imaging

At ATS 2026, a key focus is Bronchoscopic Lung Volume Reduction (BLVR), a minimally invasive treatment for severe COPD.

BLVR requires detailed imaging-based evaluation, including:

• Emphysema distribution
• Fissure completeness
• Target lobe identification

Coreline’s AI platform supports BLVR planning by providing quantitative CT analysis, helping clinicians make more informed treatment decisions.

 

Clinical Collaboration with Temple University

Coreline Soft collaborates with Temple University Hospital, a leading institution in pulmonary and interventional medicine.

This collaboration focuses on:

• Clinical validation of quantitative imaging biomarkers
• Integration of AI into real-world workflows
• Supporting research in COPD and advanced lung interventions

This reflects a broader trend at ATS:
AI adoption must be supported by clinical evidence and real-world validation.

 

AI in the ATS Ecosystem

ATS is not a technology-focused exhibition, and AI companies are not always explicitly highlighted in exhibitor lists.

However, AI is increasingly embedded across:

• Lung cancer screening
• COPD and ILD assessment
• Imaging-based disease monitoring

AI imaging solutions play a growing role in improving:

• diagnostic accuracy
• workflow efficiency
• longitudinal patient management

Meet Coreline Soft at ATS 2026 to explore AI-driven lung analysis, CAD, and BLVR planning.

 

FAQ

Is Coreline Soft participating in ATS 2026?

Yes, Coreline Soft participates in ATS 2026 as an exhibitor presenting AI lung analysis solutions.

What does Coreline showcase at ATS 2026?

Coreline presents AI-based lung analysis, CAD, and BLVR planning solutions for pulmonary diseases.

How does AI support BLVR?

AI enables quantitative CT analysis to assess emphysema distribution and identify target lobes for treatment.
 

What is CAD in lung imaging?

CAD (computer-aided detection and analysis) enables objective evaluation of lung structure and disease patterns.
 

---